Susan Cotman

Dr. Susan Cotman

Center for Genomic Medicine, Harvard Medical School, Boston, USA
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MWMichael E. Ward
Michael E. Ward
RCRobert Chen
Robert Chen
HHHsin-Yi Huang
Hsin-Yi Huang
CLConnor Ludwig
Connor Ludwig
MTMaria Telpoukhovskaia
Maria Telpoukhovskaia
AGAri J. Green
Ari J. Green
Individuals with heterozygous GRN mutations exhibit clinicopathological hallmarks of neuronal ceroid lipofuscinosis.

23 November 2013 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
XLXenia Lojewski
Xenia Lojewski
JSJohn F. Staropoli
John F. Staropoli
SBSunita Biswas-Legrand
Sunita Biswas-Legrand
ASAlexandra M. Simas
Alexandra M. Simas
LHLarissa Haliw
Larissa Haliw
Susan CotmanSusan Cotman
Susan Cotman
Neuronal ceroid lipofuscinosis (NCL) comprises ∼13 genetically distinct lysosomal disorders primarily affecting the central nervous system. Here we report successful reprograming of patient fibroblasts into induced pluripotent stem cells (iPSCs) for the two most common NCL subtypes: classic late-infantile NCL, caused by TPP1(CLN2) mutation, and juvenile NCL, caused by CLN3 mutation. CLN2/TPP1- and CLN3-iPSCs displayed overlapping but distinct biochemical and morphological abnormalities within the endosomal–lysosomal system. In neuronal derivatives, further abnormalities were observed in mitochondria, Golgi and endoplasmic reticulum. While lysosomal storage was undetectable in iPSCs, progressive disease subtype-specific storage material was evident upon neural differentiation and was rescued by reintroducing the non-mutated NCL proteins. In proof-of-concept studies, we further documented differential effects of potential small molecule TPP1 activity inducers. Fenofibrate and gemfibrozil, previously reported to induce TPP1 activity in control cells, failed to increase TPP1 activity in patient iPSC-derived neural progenitor cells. Conversely, nonsense suppression by PTC124 resulted in both an increase of TPP1 activity and attenuation of neuropathology in patient iPSC-derived neural progenitor cells. This study therefore documents the high value of this powerful new set of tools for improved drug screening and for investigating early mechanisms driving NCL pathogenesis.

10 December 2004 in BMC Neuroscience
Verified
Journal Article
Open access
PDF file
EFElisa Fossale
Elisa Fossale
PWPavlina Wolf
Pavlina Wolf
JEJanice Espinola
Janice Espinola
TLTanya Lubicz-Nawrocka
Tanya Lubicz-Nawrocka
ATAllison M Teed
Allison M Teed
Susan CotmanSusan Cotman
Susan Cotman
Background: JNCL is a recessively inherited, childhood-onset neurodegenerative disease most-commonly caused by a ~1 kb CLN3 mutation. The resulting loss of battenin activity leads to deposition of mitochondrial ATP synthase, subunit c and a specific loss of CNS neurons. We previously generated Cln3Δex7/8 knock-in mice, which replicate the common JNCL mutation, express mutant battenin and display JNCL-like pathology. Results: To elucidate the consequences of the common JNCL mutation in neuronal cells, we used P4 knock-in mouse cerebella to establish conditionally immortalized CbCln3 wild-type, heterozygous, and homozygous neuronal precursor cell lines, which can be differentiated into MAP-2 and NeuN-positive, neuron-like cells. Homozygous CbCln3Δex7/8 precursor cells express low levels of mutant battenin and, when aged at confluency, accumulate ATPase subunit c. Recessive phenotypes are also observed at sub-confluent growth; cathepsin D transport and processing are altered, although enzyme activity is not significantly affected, lysosomal size and distribution are altered, and endocytosis is reduced. In addition, mitochondria are abnormally elongated, cellular ATP levels are decreased, and survival following oxidative stress is reduced. Conclusions: These findings reveal that battenin is required for intracellular membrane trafficking and mitochondrial function. Moreover, these deficiencies are likely to be early events in the JNCL disease process and may particularly impact neuronal survival.

1 June 2015 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
UCUma Chandrachud
Uma Chandrachud
MWMathew W. Walker
Mathew W. Walker
ASAlexandra M. Simas
Alexandra M. Simas
SHSasja Heetveld
Sasja Heetveld
Anton PetcherskiAnton Petcherski
Anton Petcherski
Susan CotmanSusan Cotman
Susan Cotman
Abnormal accumulation of undigested macromolecules, often disease-specific, is a major feature of lysosomal and neurodegenerative disease and is frequently attributed to defective autophagy. The mechanistic underpinnings of the autophagy defects are the subject of intense research, which is aided by genetic disease models. To gain an improved understanding of the pathways regulating defective autophagy specifically in juvenile neuronal ceroid lipofuscinosis (JNCL or Batten disease), a neurodegenerative disease of childhood, we developed and piloted a GFP-microtubule-associated protein 1 light chain 3 (GFP-LC3) screening assay to identify, in an unbiased fashion, genotype-sensitive small molecule autophagy modifiers, employing a JNCL neuronal cell model bearing the most common disease mutation in CLN3. Thapsigargin, a sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) Ca2+ pump inhibitor, reproducibly displayed significantly more activity in the mouse JNCL cells, an effect that was also observed in human-induced pluripotent stem cell-derived JNCL neural progenitor cells. The mechanism of thapsigargin sensitivity was Ca2+-mediated, and autophagosome accumulation in JNCL cells could be reversed by Ca2+ chelation. Interrogation of intracellular Ca2+ handling highlighted alterations in endoplasmic reticulum, mitochondrial, and lysosomal Ca2+ pools and in store-operated Ca2+ uptake in JNCL cells. These results further support an important role for the CLN3 protein in intracellular Ca2+ handling and in autophagic pathway flux and establish a powerful new platform for therapeutic screening.

1 July 2012 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JSJohn F. Staropoli
John F. Staropoli
AKAmel Karaa
Amel Karaa
ELElaine Lim
Elaine Lim
AKAndrew Kirby
Andrew Kirby
NENaser Elbalalesy
Naser Elbalalesy
Susan CotmanSusan Cotman
Susan Cotman

24 June 2020 in eLife
Verified
Journal Article
Open access
JBJeremy Carlos Burns
Jeremy Carlos Burns
BCBunny Cotleur
Bunny Cotleur
DWDirk M Walther
Dirk M Walther
BBBekim Bajrami
Bekim Bajrami
SRStephen J Rubino
Stephen J Rubino
MMMichael Mingueneau
Michael Mingueneau
To date, microglia subsets in the healthy CNS have not been identified. Utilizing autofluorescence (AF) as a discriminating parameter, we identified two novel microglia subsets in both mice and non-human primates, termed autofluorescence-positive (AF+) and negative (AF−). While their proportion remained constant throughout most adult life, the AF signal linearly and specifically increased in AF+ microglia with age and correlated with a commensurate increase in size and complexity of lysosomal storage bodies, as detected by transmission electron microscopy and LAMP1 levels. Post-depletion repopulation kinetics revealed AF− cells as likely precursors of AF+ microglia. At the molecular level, the proteome of AF+ microglia showed overrepresentation of endolysosomal, autophagic, catabolic, and mTOR-related proteins. Mimicking the effect of advanced aging, genetic disruption of lysosomal function accelerated the accumulation of storage bodies in AF+ cells and led to impaired microglia physiology and cell death, suggestive of a mechanistic convergence between aging and lysosomal storage disorders.